Living Cell Technologies Ltd. (AU:1AI) has released an update.
Living Cell Technologies Ltd. is set to launch its AlgoraeOS artificial intelligence platform, which will predict drug combinations for diseases by analyzing vast medical data. The platform has already shown promising results in pre-clinical studies, particularly with AI-116 for dementia outperforming standard treatments in cell studies. Additionally, the company is advancing pre-clinical studies for AI-168, a new drug candidate targeting cardiovascular diseases.
For further insights into AU:1AI stock, check out TipRanks’ Stock Analysis page.
